New pill targets immune signals in rare lymphomas
NCT ID NCT07682792
First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time
Summary
This pilot study tests an oral drug called golidocitinib in people with two rare blood cancers: mycosis fungoides/Sézary syndrome (a type of skin lymphoma) and T-cell large granular lymphocytic leukemia. The drug blocks a protein called JAK1, which is involved in cancer cell growth. Up to 24 participants will take the pill daily to see if it can shrink tumors or improve blood cell counts.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Golidocitinib (a JAK1 inhibitor taken as a daily pill)
- What this could lead to
- If successful, this could offer a new oral treatment option for people with these rare blood cancers who have not responded to prior therapies.
- What could go wrong
- This is a small, early-phase pilot study with only 24 participants, so results may not apply broadly. The drug may cause side effects or fail to shrink tumors in many patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYCOSIS FUNGOIDES/SEZARY SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.